Last reviewed · How we verify
Intravitreal injection of Ranibizumab .5 dose
Intravitreal injection of Ranibizumab .5 dose is a Small molecule drug developed by Peter A Campochiaro, MD. It is currently in Phase 1 development.
At a glance
| Generic name | Intravitreal injection of Ranibizumab .5 dose |
|---|---|
| Sponsor | Peter A Campochiaro, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Eye pain
- Nasopharyngitis
- Influenza
- Influenza(Non-ocular)
- Vitreous floaters
- Fall
- Nasopharyngitis(Non-ocular)
- Urinary tract infection
- Fall(Non-ocular)
- Vision blurred
- Headache
- Age-related macular degeneration
Key clinical trials
- Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema (PHASE2)
- Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema (PHASE3)
- Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) (PHASE4)
- Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision (PHASE4)
- Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema (PHASE4)
- Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration (PHASE2)
- Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD (PHASE1)
- A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal injection of Ranibizumab .5 dose CI brief — competitive landscape report
- Intravitreal injection of Ranibizumab .5 dose updates RSS · CI watch RSS
- Peter A Campochiaro, MD portfolio CI
Frequently asked questions about Intravitreal injection of Ranibizumab .5 dose
What is Intravitreal injection of Ranibizumab .5 dose?
Intravitreal injection of Ranibizumab .5 dose is a Small molecule drug developed by Peter A Campochiaro, MD.
Who makes Intravitreal injection of Ranibizumab .5 dose?
Intravitreal injection of Ranibizumab .5 dose is developed by Peter A Campochiaro, MD (see full Peter A Campochiaro, MD pipeline at /company/peter-a-campochiaro-md).
What development phase is Intravitreal injection of Ranibizumab .5 dose in?
Intravitreal injection of Ranibizumab .5 dose is in Phase 1.
What are the side effects of Intravitreal injection of Ranibizumab .5 dose?
Common side effects of Intravitreal injection of Ranibizumab .5 dose include Eye pain, Nasopharyngitis, Influenza, Influenza(Non-ocular), Vitreous floaters, Fall.